Immunogenicity Risk Profile of Nanobodies

2021195 citationsJournal Articlegold Open Access

Authors

Chloé Ackaert · Vrije Universiteit Brussel

Natalia Smiejkowska · Vrije Universiteit Brussel

Catarina Xavier · Vrije Universiteit Brussel

Yann G.‐J. Sterckx · University of Antwerp

Sofie Denies · Systems Analytics (United States)

Benoı̂t Stijlemans · VIB-UGent Center for Inflammation Research

Yvon Elkrim

Abstract

Nanobodies, the recombinant single domain affinity reagents derived from heavy chain-only antibodies in camelids, are proven to possess a low immunogenicity risk profile, which will facilitate a growing number of Nanobodies to enter the clinic for therapeutic or <i>in vivo</i> diagnostic applications.

Topics & Keywords

Monoclonal and Polyclonal Antibodies Research CAR-T cell therapy research Protein purification and stability

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Frontiers in Immunology

Volume 12, pp. 632687-632687

DOI: 10.3389/fimmu.2021.632687

Field-Weighted Citation Impact: 20.06